Teladoc Health (TDOC)
Market Price (5/11/2026): $7.22 | Market Cap: $43.1 MilSector: Health Care | Industry: Health Care Technology
Teladoc Health (TDOC)
Market Price (5/11/2026): $7.22Market Cap: $43.1 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Attractive yieldFCF Yield is 293% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -88%, 3Y Excs Rtn is -153% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -157 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 664% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.5%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7%, Rev Chg QQuarterly Revenue Change % is -2.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -400% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 498% Key risksTDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 293% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -88%, 3Y Excs Rtn is -153% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -157 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 664% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.5%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7%, Rev Chg QQuarterly Revenue Change % is -2.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -400% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 498% |
| Key risksTDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share. |
Qualitative Assessment
AI Analysis | Feedback
1. Stronger-than-expected Fourth Quarter 2025 Earnings and Positive 2026 Outlook.
Teladoc Health reported its fourth quarter 2025 results on February 25, 2026, with a narrower net loss of $0.14 per share, significantly better than the $0.28 per share loss in Q4 2024 and surpassing the consensus estimate of a $0.19 loss per share. Consolidated revenue for Q4 reached $642.3 million. Notably, the Integrated Care segment saw a 5% increase in revenue to $409.1 million and a 23% rise in adjusted EBITDA to $65 million. The company also provided full-year 2026 guidance, projecting consolidated revenue between $2.47 billion and $2.59 billion, and adjusted EBITDA from $266 million to $308 million, indicating a 2% year-over-year growth at the midpoint for adjusted EBITDA. This positive earnings report contributed to a 5.92% gain in the stock price on the day of the announcement.
2. Favorable Regulatory Environment with Extended Telehealth Flexibilities.
A federal funding bill signed by President Trump on February 3, 2026, which was announced on February 5, 2026, extended crucial telehealth provisions for several years. These extensions included Medicare telehealth flexibilities until December 31, 2027, and a five-year extension for the Acute Hospital Care at Home Program through September 30, 2030. This legislative action provided increased regulatory certainty and stability for Teladoc Health and the broader telehealth industry.
Show more
Stock Movement Drivers
Fundamental Drivers
The 33.0% change in TDOC stock from 1/31/2026 to 5/10/2026 was primarily driven by a 35.4% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.45 | 7.25 | 33.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,528 | 2,514 | -0.5% |
| P/S Multiple | 0.0 | 0.0 | 35.4% |
| Shares Outstanding (Mil) | 6 | 6 | -1.2% |
| Cumulative Contribution | 33.0% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TDOC | 33.0% | |
| Market (SPY) | 3.6% | 38.7% |
| Sector (XLV) | -6.9% | 13.3% |
Fundamental Drivers
The -16.0% change in TDOC stock from 10/31/2025 to 5/10/2026 was primarily driven by a -14.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.63 | 7.25 | -16.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,528 | 2,514 | -0.5% |
| P/S Multiple | 0.0 | 0.0 | -14.5% |
| Shares Outstanding (Mil) | 6 | 6 | -1.2% |
| Cumulative Contribution | -16.0% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TDOC | -16.0% | |
| Market (SPY) | 5.5% | 42.1% |
| Sector (XLV) | 0.3% | 16.9% |
Fundamental Drivers
The 0.8% change in TDOC stock from 4/30/2025 to 5/10/2026 was primarily driven by a 6.8% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.19 | 7.25 | 0.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,570 | 2,514 | -2.1% |
| P/S Multiple | 0.0 | 0.0 | 6.8% |
| Shares Outstanding (Mil) | 6 | 6 | -3.5% |
| Cumulative Contribution | 0.8% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TDOC | 0.8% | |
| Market (SPY) | 30.4% | 42.4% |
| Sector (XLV) | 4.0% | 24.6% |
Fundamental Drivers
The -72.7% change in TDOC stock from 4/30/2023 to 5/10/2026 was primarily driven by a -71.1% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.53 | 7.25 | -72.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,407 | 2,514 | 4.5% |
| P/S Multiple | 0.1 | 0.0 | -71.1% |
| Shares Outstanding (Mil) | 5 | 6 | -9.5% |
| Cumulative Contribution | -72.7% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TDOC | -72.7% | |
| Market (SPY) | 78.7% | 40.0% |
| Sector (XLV) | 13.0% | 28.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TDOC Return | -54% | -74% | -9% | -58% | -23% | -1% | -97% |
| Peers Return | -16% | -29% | 9% | 38% | 15% | 5% | 8% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| TDOC Win Rate | 25% | 25% | 50% | 25% | 33% | 60% | |
| Peers Win Rate | 39% | 37% | 52% | 57% | 45% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| TDOC Max Drawdown | -56% | -75% | -34% | -68% | -28% | -36% | |
| Peers Max Drawdown | -32% | -45% | -29% | -31% | -18% | -29% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMWL, HIMS, DOCS, CVS, AMZN. See TDOC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | TDOC | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -24.1% | -7.8% |
| % Gain to Breakeven | 31.8% | 8.5% |
| Time to Breakeven | 34 days | 18 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -46.3% | -19.2% |
| % Gain to Breakeven | 86.3% | 23.7% |
| Time to Breakeven | 315 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -17.7% | -3.7% |
| % Gain to Breakeven | 21.5% | 3.9% |
| Time to Breakeven | 27 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -63.6% | -12.2% |
| % Gain to Breakeven | 174.5% | 13.9% |
| Time to Breakeven | 419 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -58.4% | -6.8% |
| % Gain to Breakeven | 140.3% | 7.3% |
| Time to Breakeven | 455 days | 15 days |
In The Past
Teladoc Health's stock fell -24.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TDOC | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -24.1% | -7.8% |
| % Gain to Breakeven | 31.8% | 8.5% |
| Time to Breakeven | 34 days | 18 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -46.3% | -19.2% |
| % Gain to Breakeven | 86.3% | 23.7% |
| Time to Breakeven | 315 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -63.6% | -12.2% |
| % Gain to Breakeven | 174.5% | 13.9% |
| Time to Breakeven | 419 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -58.4% | -6.8% |
| % Gain to Breakeven | 140.3% | 7.3% |
| Time to Breakeven | 455 days | 15 days |
In The Past
Teladoc Health's stock fell -24.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Teladoc Health (TDOC)
AI Analysis | Feedback
Here are 1-3 brief analogies for Teladoc Health:
Amazon for healthcare
Uber for doctor visits
AI Analysis | Feedback
- Primary and Specialty Care Telehealth Solutions: Provides virtual consultations with doctors for general health concerns and specialized medical conditions.
- Chronic Condition Management: Offers digital programs and support for individuals managing chronic illnesses such as diabetes, hypertension, and heart failure.
- Expert Medical Services: Connects members with top medical experts for second opinions, complex diagnoses, and treatment plan guidance.
- Mental Health Solutions: Delivers virtual therapy, psychiatry, and mental wellness programs to address a range of behavioral health needs.
- Platform and Program Services: Provides the underlying technology platform and comprehensive program management for clients to offer virtual care to their members.
AI Analysis | Feedback
Teladoc Health (TDOC) serves a diverse range of major customers, primarily other companies, as well as individual members. Based on the provided background information, its major customer segments include:
- Employers
- Health plans
- Hospitals and health systems
- Insurance and financial services companies
- Individual members
The background information describes categories of customers rather than listing specific company names or their stock symbols.
AI Analysis | Feedback
Chuck Divita, III Chief Executive Officer
Chuck Divita, III was appointed CEO of Teladoc Health in June 2024. Prior to this, he held senior leadership positions at GuideWell, a large health solutions organization that includes Florida Blue, where he served as Executive Vice President for Commercial Markets and Chief Financial Officer. Before joining GuideWell, Mr. Divita was the Chief Financial Officer of FPIC Insurance Group, a publicly traded property and casualty insurer. He has a reputation as an innovative, results-driven leader in the healthcare industry, recognized for driving growth and advancing new healthcare models. He has also served on the boards of various healthcare companies, including Prime Therapeutics, Availity, and VIM.
Mala Murthy Chief Financial Officer
Mala Murthy has served as the CFO of Teladoc Health since June 2019. She also served as acting Chief Executive Officer from April to June 2024. Before joining Teladoc Health, Ms. Murthy held several senior executive positions at American Express, including Chief Financial Officer of the Global Commercial Services segment. Prior to American Express, she held various leadership positions with PepsiCo, where she notably led high-growth business units and oversaw financial planning and analysis, corporate and international treasury, and corporate strategy. She has a proven track record of supporting multi-billion-dollar acquisitions and developing capital structure and liquidity strategies.
Dr. Vidya Raman-Tangella Chief Medical Officer
Dr. Vidya Raman-Tangella was named Chief Medical Officer of Teladoc Health in April 2022. In this role, she leads the company's enterprise clinical strategy, quality, and research efforts, with a focus on areas such as health equity and clinical evidence. Before joining Teladoc Health, Dr. Raman-Tangella was the general manager of Healthcare and Life Sciences Solutions at AWS (Amazon Web Services), where she developed strategies and solutions for the healthcare ecosystem. Her career includes leadership roles at prominent healthcare companies such as Blue Cross Blue Shield, Johnson & Johnson, and UnitedHealthcare, where she focused on designing integrated health and wellness solutions for employers and health plans. Her expertise lies in leveraging science, data, technology, and partnerships to create healthcare solutions for disease prevention, personalized patient experiences, and healthcare access.
Carlos Nueno President, International
Carlos Nueno is the President of International operations for Teladoc Health, a role he has held since July 2018. He is responsible for the strategic direction, operations, and client management of Teladoc Health's global footprint. Mr. Nueno co-founded and served as CEO of Advance Medical from 1999 to 2018, leading its growth to become a global provider of health services with over 900 employees across North America, Europe, and Asia. Advance Medical was acquired by Teladoc Health in 2018. Earlier in his career, he worked as a consultant for Gemini Consulting.
Kelly Bliss President, U.S. Group Health
Kelly Bliss is the President of Teladoc Health's U.S. Group Health business. She is responsible for overseeing strategy, partnerships, product management, marketing, sales, operations, and client management for virtual care services that reach over 100 million covered Americans. Prior to this role, Ms. Bliss served as Teladoc's Chief Client Officer from 2017 to 2020, where she was instrumental in achieving record client satisfaction and retention through a focus on delivering value and a best-in-class experience. She also played a key role in the integration efforts of several acquisitions, including the integration of Best Doctors after its acquisition by Teladoc Health in 2017, where she had previously served as Chief of Staff. Additionally, she contributed to integrating Livongo's chronic care management solutions after its acquisition by Teladoc Health. Ms. Bliss has built and managed high-performing global teams at companies such as Best Doctors and InterSystems.
AI Analysis | Feedback
The key risks to Teladoc Health (TDOC) primarily revolve around intense market competition, ongoing struggles with its BetterHelp segment impacting overall profitability, and the lasting repercussions of its significant acquisitions.
- Intense Competition and Profitability Challenges: Teladoc Health operates in a highly competitive virtual healthcare market, facing pressure from traditional healthcare providers, new telehealth entrants, and large technology and retail companies expanding into healthcare. This environment leads to pricing pressure and difficulties in attracting and retaining users. A significant contributor to Teladoc's overall profitability struggles is its BetterHelp segment, which has experienced declining revenue and user numbers due to high customer acquisition costs. This segment's underperformance acts as a drag on the company's growth trajectory and its path to consistent profitability, with analysts not forecasting a full year of profitability until 2025 or later. The company has also recorded recurring goodwill impairment charges, reflecting past acquisitions not living up to their valuations.
- Integration and Performance of Acquisitions: A major strategic move, the acquisition of Livongo in 2020, has been cited as a source of significant challenges. Issues included a high acquisition cost, difficulties in integrating the different company cultures and operating models, and a failure to quickly achieve expected synergies. These problems have contributed to substantial goodwill impairment charges and negative investor sentiment. While the company has worked to address these integration issues and a securities lawsuit related to the Livongo integration was dismissed, the ongoing struggles of the BetterHelp segment, which stemmed from this acquisition, continue to pose a risk to Teladoc's financial performance.
- Regulatory and Reimbursement Uncertainty: As a provider of virtual healthcare services, Teladoc Health is highly susceptible to changes in healthcare laws, regulations, and reimbursement policies. The regulatory landscape for telehealth is dynamic, and shifts in government or private insurer reimbursement models could significantly impact the accessibility, demand, and profitability of Teladoc's services. The longevity of temporary regulatory changes that expanded telehealth access during the COVID-19 pandemic remains uncertain, requiring Teladoc to adapt to potential reversions that could affect service offerings and revenue.
AI Analysis | Feedback
1. Amazon's expansion into virtual primary care and chronic condition management: With initiatives like Amazon Clinic and the acquisition of One Medical, Amazon is a well-resourced, consumer-centric player directly entering Teladoc's core virtual care markets. Amazon's ability to bundle services, leverage its vast customer base, and utilize its logistics infrastructure poses a significant competitive threat, potentially disrupting established pricing models and customer acquisition strategies.
2. Vertical integration by major health plans and health systems: Large health plans (e.g., UnitedHealth Group's Optum, Cigna's Evernorth with MDLive, CVS Health/Aetna) are increasingly building out their own comprehensive virtual care platforms and directly acquiring or employing providers. Similarly, major health systems are enhancing their in-house telehealth capabilities, often integrating them deeply with their existing services. This trend could reduce their reliance on third-party virtual care providers like Teladoc, leading to increased competition for Teladoc's client base of employers and health plans, and potentially disintermediating Teladoc from parts of the care delivery chain.
AI Analysis | Feedback
Teladoc Health (symbol: TDOC) operates within several substantial addressable markets for its virtual healthcare services and solutions.
Virtual Healthcare Services (Telehealth/Telemedicine)
- The global telehealth market was estimated at approximately USD 123.26 billion in 2024 and is projected to reach USD 455.27 billion by 2030, growing at a CAGR of 24.68% from 2025 to 2030.
- Another estimate places the global telehealth market size at USD 126.1 billion in 2024, anticipated to grow to USD 403.2 billion by 2034, at a CAGR of 12.4% from 2025 to 2034.
- The U.S. telehealth market generated a revenue of USD 42,540.9 million in 2024 and is expected to reach USD 150,131.3 million by 2030, with a CAGR of 23.8% from 2025 to 2030.
- The U.S. virtual care market was estimated at USD 8.83 billion in 2024 and is expected to grow at a CAGR of 32.35% from 2025 to 2030. Another projection for the U.S. virtual care market indicates a value of USD 12.48 billion in 2025, reaching USD 206.74 billion by 2035 at a CAGR of 32.39% from 2026 to 2035.
- Teladoc Health has stated its combined total addressable market in the telehealth space is approximately USD 121 billion.
Chronic Condition Management
- The global chronic disease management market was valued at USD 8.33 billion in 2024 and is expected to reach USD 27.90 billion by 2032, with a CAGR of 16.30% from 2025 to 2032.
- Another report values the global chronic disease management market at USD 5.82 billion in 2024, projected to increase to USD 20.87 billion by 2034, expanding at a CAGR of 13.62% from 2025 to 2034.
- The U.S. chronic disease management market size was USD 1.75 billion in 2024 and is projected to be worth around USD 6.38 billion by 2034, growing at a CAGR of 13.80% from 2025 to 2034.
Mental Health Solutions
- The global mental health market size is forecast to increase by USD 153.3 billion at a CAGR of 6.8% between 2024 and 2029.
- The mental health apps market globally is projected to reach USD 22.73 billion by 2030, from USD 9.94 billion in 2025, at a CAGR of 18.0% during the forecast period.
- North America is estimated to contribute 36% to the growth of the global mental health market during the forecast period.
AI Analysis | Feedback
Teladoc Health (TDOC) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market shifts:
- Transition to Visit-Oriented Models and Growth in Integrated Care: Teladoc Health is strategically shifting its U.S. virtual care subscriptions from traditional subscription-based models to more visit-oriented models, which are more reflective of the U.S. healthcare fee-for-service construct. While this shift may initially impact subscription revenue, the company anticipates that growth in visit volumes will become a key driver of overall revenue in the long term. The Integrated Care segment, which serves health plans, employers, and health systems, is projected to see revenue growth between 0.4% and 3.9% in 2026, with contributions from recent acquisitions.
- Scaling BetterHelp's Insurance Offering: The BetterHelp segment, Teladoc Health's virtual mental health platform, is undergoing a significant transition from a cash-pay model to an in-network, insurance-covered model. This expansion into accepting insurance is identified as a major growth opportunity, with Teladoc Health forecasting BetterHelp's insurance revenue to range from $75 million to $90 million in 2026, with an annualized revenue run rate exceeding $100 million.
- International Market Expansion: Teladoc Health is actively pursuing growth in international markets, with expectations for double-digit revenue growth from its international segment in 2026. The company is expanding its presence and establishing partnerships in new regions, including France, Germany, the Netherlands, Spain, and Austria.
- New Innovations and AI Advancements in Integrated Care: The company is investing in new innovations and capabilities within its Integrated Care products, particularly through advancements in artificial intelligence. The Pulse platform, for instance, is designed to unify extensive data, apply intelligence, and connect AI-driven insights to patient care, thereby enhancing virtual care offerings and supporting future growth.
AI Analysis | Feedback
Share Repurchases
- Teladoc Health reported no share repurchases for the trailing twelve months ended September 2025, and $0 million for the three months ended September 2025.
Share Issuance
- On May 22, 2025, Teladoc Health’s stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6.85 million.
- In Q4 2025, Teladoc Health had 178 million shares outstanding, representing a 0.5% increase from the prior quarter.
- The company announced an employee inducement award under NYSE Rule 303A.08 on March 4, 2026, for a new employee.
Outbound Investments
- In April 2025, Teladoc Health acquired digital mental health company UpLift for $45 million, consisting of $30 million cash and up to $15 million in contingent earnouts, to expand its virtual mental health services.
- In February 2025, Teladoc Health signed an agreement to acquire virtual preventive care company Catapult Health for $65 million, with an additional $5 million in contingent earnout consideration, aiming to enhance chronic condition management and at-home diagnostic testing.
- Teladoc Health acquired Telecare, a provider of teleconsultation services, in August 2025.
Capital Expenditures
- Capital expenditures and capitalized software development costs totaled $127.5 million for the full year 2025, an increase from $124.1 million in 2024.
- For the first nine months of 2025, capital expenditures and capitalized software development costs were $93.1 million, compared to $94.4 million in the first nine months of 2024.
- The capital expenditures are focused on necessary investments in the company's platform and technology, product innovation, enhanced cardiometabolic programs, integrated mental health offerings, and international expansion.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Teladoc Health Earnings Notes | 12/16/2025 | |
| How Low Can Teladoc Health Stock Really Go? | 10/17/2025 | |
| Teladoc Health (TDOC) Revenue Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) Operating Income Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) Net Income Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) Debt Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) EBITDA Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) Operating Cash Flow Comparison | 08/09/2025 | |
| Teladoc Health (TDOC) Tax Expense Comparison | 08/09/2025 | |
| TDOC Dip Buy Analysis | 07/10/2025 | |
| ARTICLES | ||
| What’s Next For Teladoc Stock After An 89% Fall In Three Years? | 07/07/2023 | |
| Teladoc, CRISPR: Finally Time To Buy Beaten Down Healthcare Names? | 06/08/2022 | |
| Down 20% In A Month, Is Teladoc Stock A Buy? | 01/25/2022 | |
| Here’s Why Teladoc Stock Looks Attractive At $140 | 05/17/2021 |
Trade Ideas
Select ideas related to TDOC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 04302024 | TDOC | Teladoc Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -30.0% | -43.6% | -48.9% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 27.12 |
| Mkt Cap | 5.6 |
| Rev LTM | 2,431 |
| Op Inc LTM | 172 |
| FCF LTM | 92 |
| FCF 3Y Avg | 201 |
| CFO LTM | 308 |
| CFO 3Y Avg | 276 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.9% |
| Rev Chg 3Y Avg | 9.8% |
| Rev Chg Q | 8.0% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Inc Chg LTM | 17.5% |
| Op Inc Chg 3Y Avg | 27.3% |
| Op Mgn LTM | 3.7% |
| Op Mgn 3Y Avg | 2.4% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 12.1% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 2.1% |
| FCF/Rev 3Y Avg | 5.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.6 |
| P/S | 1.6 |
| P/Op Inc | 15.1 |
| P/EBIT | 19.0 |
| P/E | 26.3 |
| P/CFO | 13.3 |
| Total Yield | 2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.7% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 32.8% |
| 3M Rtn | 26.2% |
| 6M Rtn | 3.9% |
| 12M Rtn | 9.2% |
| 3Y Rtn | 12.9% |
| 1M Excs Rtn | 22.0% |
| 3M Excs Rtn | 19.5% |
| 6M Excs Rtn | -9.4% |
| 12M Excs Rtn | -19.8% |
| 3Y Excs Rtn | -70.9% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Integrated Care | 1,529 | 1,469 | 1,374 | 1,301 | |
| BetterHelp | 1,041 | 1,134 | 1,020 | 721 | |
| Other | 0 | 13 | 11 | 25 | |
| Access Fees Revenue | 847 | ||||
| Visit Fee Revenue | 222 | ||||
| Total | 2,570 | 2,602 | 2,407 | 2,033 | 1,094 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Integrated Care | 233 | 192 | 135 | ||
| BetterHelp | 78 | 136 | 114 | ||
| Acquisition, integration, and transformation costs | -2 | -21 | -16 | ||
| Depreciation of property and equipment | -10 | -11 | -11 | ||
| Restructuring costs | -20 | -17 | -7 | ||
| Stock-based compensation | -146 | -202 | -218 | ||
| Amortization of intangible assets | -363 | -326 | -245 | ||
| Goodwill impairment | -790 | 0 | -13,403 | ||
| Other | 0 | -3 | |||
| Total | -1,021 | -249 | -13,653 |
Price Behavior
| Market Price | $7.25 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/01/2015 | |
| Distance from 52W High | -23.4% | |
| 50 Days | 200 Days | |
| DMA Price | $5.63 | $6.84 |
| DMA Trend | down | up |
| Distance from DMA | 28.8% | 6.0% |
| 3M | 1YR | |
| Volatility | 56.3% | 57.0% |
| Downside Capture | -0.22 | 0.97 |
| Upside Capture | 135.44 | 135.43 |
| Correlation (SPY) | 33.4% | 41.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.62 | 1.30 | 1.47 | 1.53 | 1.92 | 1.52 |
| Up Beta | 0.49 | 0.47 | 0.89 | 1.43 | 1.91 | 1.20 |
| Down Beta | 4.78 | 2.73 | 2.63 | 1.62 | 2.31 | 1.26 |
| Up Capture | 105% | 154% | 147% | 105% | 158% | 249% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 20 | 26 | 50 | 112 | 343 |
| Down Capture | 105% | 116% | 143% | 173% | 166% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 21 | 36 | 72 | 133 | 400 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TDOC | |
|---|---|---|---|---|
| TDOC | 9.4% | 56.9% | 0.36 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 22.6% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 42.4% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 9.6% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -4.7% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 30.7% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 33.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TDOC | |
|---|---|---|---|---|
| TDOC | -46.0% | 63.4% | -0.70 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 31.8% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 46.5% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 6.8% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 4.8% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 38.9% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 27.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TDOC | |
|---|---|---|---|---|
| TDOC | -4.7% | 60.4% | 0.18 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 27.6% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 35.8% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 6.7% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 5.9% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 22.6% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/25/2026 | 15.1% | 10.3% | 18.7% |
| 10/23/2025 | 10.0% | 1.6% | -19.1% |
| 7/29/2025 | -1.7% | -7.6% | 2.8% |
| 2/26/2025 | -13.6% | -17.8% | -22.1% |
| 10/30/2024 | 1.6% | 6.5% | 35.2% |
| 7/31/2024 | -8.9% | -24.1% | -24.7% |
| 2/20/2024 | -23.7% | -26.0% | -24.8% |
| 10/24/2023 | -3.9% | -8.7% | -5.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 6 |
| # Negative | 10 | 10 | 12 |
| Median Positive | 8.1% | 8.4% | 4.6% |
| Median Negative | -7.9% | -12.2% | -19.1% |
| Max Positive | 27.0% | 21.8% | 35.2% |
| Max Negative | -23.7% | -26.0% | -30.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 04/26/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 10/27/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | 597.00 Mil | 611.50 Mil | 626.00 Mil | 0.4% | Raised | Guidance: 609.00 Mil for Q1 2026 | |
| Q2 2026 Adjusted EBITDA | 55.00 Mil | 61.00 Mil | 67.00 Mil | 8.9% | Raised | Guidance: 56.00 Mil for Q1 2026 | |
| Q2 2026 Net loss per share | -0.3 | -0.25 | -0.2 | ||||
| 2026 Revenue | 2.48 Bil | 2.53 Bil | 2.58 Bil | 0 | Affirmed | Guidance: 2.53 Bil for 2026 | |
| 2026 Adjusted EBITDA | 267.00 Mil | 286.50 Mil | 306.00 Mil | -0.2% | Lowered | Guidance: 287.00 Mil for 2026 | |
| 2026 Net loss per share | -1.05 | -0.9 | -0.75 | ||||
| 2026 Free Cash Flow | 130.00 Mil | 150.00 Mil | 170.00 Mil | 0 | Affirmed | Guidance: 150.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 598.00 Mil | 609.00 Mil | 620.00 Mil | -4.4% | Lower New | Actual: 637.00 Mil for Q4 2025 | |
| Q1 2026 Adjusted EBITDA | 50.00 Mil | 56.00 Mil | 62.00 Mil | -31.3% | Lower New | Actual: 81.50 Mil for Q4 2025 | |
| 2026 Revenue | 2.47 Bil | 2.53 Bil | 2.59 Bil | 0.2% | Higher New | Actual: 2.52 Bil for 2025 | |
| 2026 Adjusted EBITDA | 266.00 Mil | 287.00 Mil | 308.00 Mil | 3.1% | Higher New | Actual: 278.50 Mil for 2025 | |
| 2026 Free Cash Flow | 130.00 Mil | 150.00 Mil | 170.00 Mil | -15.5% | Lower New | Actual: 177.50 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Divita, Charles Iii | CHIEF EXECUTIVE OFFICER | Direct | Sell | 3122026 | 5.49 | 27,731 | 152,243 | 2,002,664 | Form |
| 2 | Rodrigues, Fernando M | President of BetterHelp | Direct | Sell | 3032026 | 4.98 | 25,086 | Form | ||
| 3 | Vandervoort, Adam C | CHIEF LEGAL OFFICER, SECRETARY | Direct | Sell | 3032026 | 5.12 | 27,083 | 138,584 | 528,274 | Form |
| 4 | Nueno, Carlos | President, International | Direct | Sell | 3032026 | 5.12 | 20,165 | 103,184 | 258,895 | Form |
| 5 | Rodrigues, Fernando M | President of BetterHelp | Direct | Sell | 3032026 | 5.12 | 16,314 | 83,479 | 128,365 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.